4/3/2009

Michael Narachi, formerly with Ren Pharmaceuticals and Amgen, was appointed president and CEO of Orexigen Therapeutics, succeeding interim CEO and co-founder Eckard Weber. Orexigen plans to submit its obesity drug Contrave for FDA approval in the first half of next year.

Related Summaries